Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial

Neurology

Volumn 66, Issue 3, 2006, Pages 324-330

  Kaufmann, P ^a,e   Engelstad, K ^a   Wei, Y ^a   Jhung, S ^a   Sano, M C ^b   Shungu, D C ^c   Millar, W S ^a   Hong, X ^a   Gooch, C L ^a   Mao, X ^c   Pascual, J M ^a   Hirano, M ^a   Stacpoole, P W ^d   DiMauro, S ^a   De Vivo, D C ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; LACTIC ACID; PLACEBO;

ADULT; ARTICLE; BLOOD ANALYSIS; BRAIN VENTRICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GLOBAL ASSESSMENT OF TREATMENT EFFICACY SCORE; HUMAN; LACTIC ACIDOSIS; LIVER DYSFUNCTION; MALE; MELAS SYNDROME; NERVE CELL LESION; NERVE CONDUCTION; NEUROPATHY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SPECTROSCOPY; STROKE; ACTION POTENTIAL; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PERONEUS NERVE; SURAL NERVE;

ACTION POTENTIALS; ADOLESCENT; ADULT; CHILD; CROSS-OVER STUDIES; DICHLOROACETATE; DOUBLE-BLIND METHOD; HUMANS; MELAS SYNDROME; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PERONEAL NERVE; SURAL NERVE;

EID: 33646202306     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000196641.05913.27     Document Type: Article

References (26)

1. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol 1994;9:4-13.
2. Goto Y, Nonaka I, Horai S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim Biophys Acta 1991;1097:238-240.
3. De Vivo DC. The expanding clinical spectrum of mitochondrial diseases. Brain Dev 1993;15:1-22.
4. De Vivo DC, Shungu DC, Millar W, Di Mauro S. Does dichloroacetate minimize the neurotoxicity of chronic cerebral acidosis? Ann Neurol 1996:318. Abstract.
5. De Vivo DC. Cerebral energy failure. Curr Neurol Neurosci Rep 2001;1:203-204.
6. Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-1302.
7. Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 1992;327:1564-1569.
8. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997;77:535-541.
9. De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45:1193-1198.
10. Taivassalo T, Matthews PM, De Stefano N, et al. Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency. Neurology 1996;47:529-534.
11. Saitoh S, Momoi MY, Yamagata T, Mori Y, Imai M. Effects of dichloroacetate in three patients with MELAS. Neurology 1998;50:531-534.
12. Kimura S, Ohtuki N, Nezu A, Tanaka M, Takeshita S. Clinical and radiologic improvements in mitochondrial encephalomyelopathy following sodium dichloroacetate therapy. Brain Dev 1997;19:535-540.
13. Mori M, Yamagata T, Goto T, Saito S, Momoi MY. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 2004;26:453-458.
14. Saijo T, Naito E, Ito M, Takeda E, Hashimoto T, Kuroda Y. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 1991;22:166-167.
15. Barshop BA, Naviaux RK, McGowan KA, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab 2004;83:138-149.
16. Sudo A, Sasaki M, Sugai K, Matsuda H. Therapeutic effect and [123I]IMP SPECT findings of sodium dichloroacetate in a patient with MELAS. Neurology 2004;62:338-339.
17. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539.
18. Spruijt L, Naviaux RK, McGowan KA, et al. Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve 2001;24:916-924.
19. Karppa M, Syrjala P, Tolonen U, Majamaa K. Peripheral neuropathy in patients with the 3243A>G mutation in mitochondrial DNA. J Neurol 2003;250:216-221.
20. DeVivo DC, Haymond MW, Obert KA, Nelson JS, Pagliara AS. Defective activation of the pyruvate dehydrogenase complex in subacute necrotizing encephalomyelopathy (Leigh disease). Ann Neurol 1979;6:483-494.
21. Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983;309:390-396.
22. Kuroda Y, Ito M, Naito E, et al. Concomitant administration of sodium dichloroacetate and vitamin B1 for lactic acidemia in children with MELAS syndrome. J Pediatr 1997;131:450-452.
23. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002;15:633-638.
24. Stacpoole PW, Perkins LA, Neiberger NE, Theriaque DW, Hutson AD. Dichloroacetate treatment of congenital lactic acidosis: preliminary outcome results of the DCA/CLA clinical trial [abstract]. Presented at the 84th annual meeting of The Endocrine Society; San Francisco, CA; June 2002.
25. Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology, and therapy. Curr Neurol Neurosci Rep 2004;4:55-61.
26. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824.